COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network
- DOI
- 10.1111/irv.70120
- Published
- 2025-05
- Container
- Influenza and Other Respiratory Viruses
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/irv.70120,
title = {COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network},
author = {Charlotte Laniece Delaunay and Nuno Verdasca and Susana Monge and Lisa Domegan and Noémie Sève and Silke Buda and Adam Meijer and Héloïse Lucaccioni and Miriam López Torrijos and Adele McKenna and Vincent Enouf and Ralf Dürrwald and Eline In't Velt and Mª Ángel de Valcárcel Laiglesia and Charlene Bennett and Shirley Masse and Annika Erdwiens and Mariette Hooiveld and Ivan Mlinarić and Gergő Túri and Ana Paula Rodrigues and Iván Martínez‐Baz and Mihaela Lazar and Neus Latorre‐Margalef and Vitor Borges and Marlena Kaczmarek and Sabrina Bacci and Esther Kissling and Unknown},
year = {2025},
journal = {Influenza and Other Respiratory Viruses},
doi = {10.1111/irv.70120},
url = {https://doi.org/10.1111/irv.70120}
}RIS
TY - JOUR TI - COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network AU - Charlotte Laniece Delaunay AU - Nuno Verdasca AU - Susana Monge AU - Lisa Domegan AU - Noémie Sève AU - Silke Buda AU - Adam Meijer AU - Héloïse Lucaccioni AU - Miriam López Torrijos AU - Adele McKenna AU - Vincent Enouf AU - Ralf Dürrwald AU - Eline In't Velt AU - Mª Ángel de Valcárcel Laiglesia AU - Charlene Bennett AU - Shirley Masse AU - Annika Erdwiens AU - Mariette Hooiveld AU - Ivan Mlinarić AU - Gergő Túri AU - Ana Paula Rodrigues AU - Iván Martínez‐Baz AU - Mihaela Lazar AU - Neus Latorre‐Margalef AU - Vitor Borges AU - Marlena Kaczmarek AU - Sabrina Bacci AU - Esther Kissling AU - Unknown PY - 2025 JO - Influenza and Other Respiratory Viruses DO - 10.1111/irv.70120 UR - https://doi.org/10.1111/irv.70120 ER -
APA
Delaunay, C. L., Verdasca, N., Monge, S., Domegan, L., Sève, N., Buda, S., Meijer, A., Lucaccioni, H., Torrijos, M. L., McKenna, A., Enouf, V., Dürrwald, R., Velt, E. I., Laiglesia, M. Á. D. V., Bennett, C., Masse, S., Erdwiens, A., Hooiveld, M., Mlinarić, I., Túri, G., Rodrigues, A. P., Martínez‐Baz, I., Lazar, M., Latorre‐Margalef, N., Borges, V., Kaczmarek, M., Bacci, S., Kissling, E., & Unknown (2025). COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70120
Source records
- crossref · retrieved 2026-09-25T05:13:02.416Z